{"filing":{"accession_number":"0001575872-26-000725","cik":"0001135951","ticker":"RDY","company_name":"DR REDDYS LABORATORIES LTD","form":"6-K","filing_date":"2026-10-23","report_date":"2026-10-23","primary_document":"rdy0952_6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1135951/000157587226000725/rdy0952_6k.htm"},"events":[{"id":37544,"run_id":34603,"accession_number":"0001575872-26-000725","anchor_item_number":"EX-99.2","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a press release announcing Dr. Reddy's consolidated financial results for Q2 and H1 FY27 (quarter and six months ended September 30, 2026). It presents comprehensive financial statements including revenues (₹86.7 billion for Q2, ₹167.4 billion for H1), EBITDA, profit before and after tax, EPS, and detailed segment breakdowns. The document explicitly states \"Dr. Reddy's Q2 \u0026 H1FY27 Financial Results\" and includes management commentary from the Co-Chairman \u0026 MD. This is a discrete earnings announcement, not a periodic financial report filing itself.","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-10-23","form":"6-K","submitted_at":null,"items":[{"id":42290,"accession_number":"0001575872-26-000725","item_number":"EX-99.2","item_title":"rdy0952_ex99-2.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing Dr. Reddy's consolidated financial results for Q2 and H1 FY27 (quarter and six months ended September 30, 2026). It presents comprehensive financial statements including revenues (₹86.7 billion for Q2, ₹167.4 billion for H1), EBITDA, profit before and after tax, EPS, and detailed segment breakdowns. The document explicitly states \"Dr. Reddy's Q2 \u0026 H1FY27 Financial Results\" and includes management commentary from the Co-Chairman \u0026 MD. This is a discrete earnings announcement, not a periodic financial report filing itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T18:44:50.365100+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42289,"accession_number":"0001575872-26-000725","item_number":"EX-99.1","item_title":"rdy0952_ex99-1.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is a formal notification letter from Dr. Reddy's Laboratories announcing Board approval of unaudited financial results for the quarter and half-year ended September 30, 2026, prepared under both IFRS and Ind AS standards. The disclosure explicitly references \"Unaudited Consolidated Financial Results\" and \"Unaudited Standalone Financial Results\" for the interim period, along with a press release and limited review reports. This is a periodic interim financial report filing, not a discrete earnings event, and should be deferred for separate processing as the underlying financial statements themselves.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T18:44:50.365100+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-10-23"},{"id":42290,"accession_number":"0001575872-26-000725","item_number":"EX-99.2","item_title":"rdy0952_ex99-2.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a press release announcing Dr. Reddy's consolidated financial results for Q2 and H1 FY27 (quarter and six months ended September 30, 2026). It presents comprehensive financial statements including revenues (₹86.7 billion for Q2, ₹167.4 billion for H1), EBITDA, profit before and after tax, EPS, and detailed segment breakdowns. The document explicitly states \"Dr. Reddy's Q2 \u0026 H1FY27 Financial Results\" and includes management commentary from the Co-Chairman \u0026 MD. This is a discrete earnings announcement, not a periodic financial report filing itself.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T18:44:50.365100+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-10-23"},{"id":42291,"accession_number":"0001575872-26-000725","item_number":"EX-99.3","item_title":"rdy0952_ex99-3.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":true,"confidence":0.95,"reasoning":"This exhibit is Dr. Reddy's Laboratories' unaudited consolidated financial results for the quarter and half-year ended 30 September 2026, prepared in accordance with IFRS. It presents comprehensive interim financial statements including consolidated statements of comprehensive income, financial position, and cash flows, along with segment information and detailed notes. This is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete earnings-release event, and should be deferred for separate processing as a periodic filing.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T18:44:50.365100+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-10-23"},{"id":42292,"accession_number":"0001575872-26-000725","item_number":"EX-99.4","item_title":"rdy0952_ex99-4.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an independent auditor's review report and accompanying unaudited consolidated financial statements for the quarter and half-year ended September 30, 2026. It is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings release. The document includes a consolidated balance sheet, income statement, cash flow statement, and segment information prepared in accordance with Ind AS 34 \"Interim Financial Reporting\" and reviewed by Deloitte Haskins \u0026 Sells LLP. Routine periodic financial reporting is not material as a disclosure event.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T18:44:50.365100+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-10-23"},{"id":42293,"accession_number":"0001575872-26-000725","item_number":"EX-99.5","item_title":"rdy0952_ex99-5.htm","event_type":"periodic_interim","event_domain":"periodic","is_material":false,"confidence":0.95,"reasoning":"This exhibit is an independent auditor's review report and accompanying unaudited standalone financial results for the quarter and half-year ended September 30, 2026, prepared in accordance with Ind AS 34 and SEBI Listing Regulations. It is a periodic interim financial report (the foreign-issuer equivalent of a 10-Q), not a discrete event or earnings press release. The auditor's conclusion is unmodified, and the financial statements are presented as a formal filing requirement, not as a news announcement.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-23T18:44:50.365100+00:00","company_name":"DR REDDYS LABORATORIES LTD","ticker":"RDY","filing_date":"2026-10-23"}]}